Take­da touts in­ter­im PhI­II da­ta of en­zyme re­place­ment ther­a­py for rare blood dis­ease

Take­da says in an in­ter­im Phase III analy­sis that its en­zyme re­place­ment ther­a­py re­duced in­stances of low blood platelet count for pa­tients with a rare …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.